Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

BACKGROUND: The clinical use of BRAF inhibitors for treatment of metastatic melanoma is limited by the development of drug resistance. In this study we investigated whether co-targeting the MAPK and the PI3K-AKT pathway can prevent emergence of resistance or provide additional growth inhibitory effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lassen, Amanda, Atefi, Mohammad, Robert, Lidia, Wong, Deborah JL, Cerniglia, Michael, Comin-Anduix, Begonya, Ribas, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021505/
https://www.ncbi.nlm.nih.gov/pubmed/24735930
http://dx.doi.org/10.1186/1476-4598-13-83

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021505/
https://www.ncbi.nlm.nih.gov/pubmed/24735930
http://dx.doi.org/10.1186/1476-4598-13-83

Ejemplares similares